The Global CEO Initiative on Alzheimer’s Disease works with governments, NGO’s, scientists and other critical stakeholders in the technology, payer, provider and finance industries to achieve the shared goals of preventing and effectively treating Alzheimer’s disease by 2025 and enhancing the quality of life of those with the disease and those who care for them.
While in its formative stage, the following corporations are currently engaged in developing this Initiative:
- AC Immune
- Bank of America
- Elan Corporation
- Eli Lilly & Company
- GE Healthcare
- Janssen Alzheimer's Immunotherapy Research & Development, LLC
- Merck Inc.
- Nestlé S.A
- Pfizer, Inc.
- Sanofi SA
The Initiative will include corporations from an array of industries including pharmaceutical, biotechnology, IT, insurance and financial services sectors as well as general business, particularly those with a large base of employees, many of whom may be impacted by Alzheimer's direction. The Initiative will also link to and partner with ReACT (Respect a Caregivers Time), an existing coalition and corporate leadership initiative focused on addressing the needs of employee caregivers.
In addition to the corporate formational members, the following non-profit organizations are engaged and will be leading or participating in the working groups: